Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1989 May;52(5):631–635. doi: 10.1136/jnnp.52.5.631

Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.

A Braun 1, M M Mouradian 1, E Mohr 1, G Fabbrini 1, T N Chase 1
PMCID: PMC1032178  PMID: 2567345

Abstract

The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnoli A., Ruggieri S., Del Roscio S., Baldassarre M., Bocola V., Denaro A. Abnormal involuntary movements: a study of dopaminergic receptor interaction. Adv Neurol. 1983;37:305–312. [PubMed] [Google Scholar]
  2. Arnt J., Hyttel J., Perregaard J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol. 1987 Jan 13;133(2):137–145. doi: 10.1016/0014-2999(87)90144-0. [DOI] [PubMed] [Google Scholar]
  3. Barone P., Tucci I., Parashos S. A., Chase T. N. D-1 dopamine receptor changes after striatal quinolinic acid lesion. Eur J Pharmacol. 1987 Jun 12;138(1):141–145. doi: 10.1016/0014-2999(87)90351-7. [DOI] [PubMed] [Google Scholar]
  4. Braun A. R., Barone P., Chase T. N. Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. Adv Exp Med Biol. 1986;204:151–166. doi: 10.1007/978-1-4684-5191-7_10. [DOI] [PubMed] [Google Scholar]
  5. Braun A. R., Chase T. N. Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists. Eur J Pharmacol. 1988 Mar 15;147(3):441–451. doi: 10.1016/0014-2999(88)90179-3. [DOI] [PubMed] [Google Scholar]
  6. Braun A. R., Chase T. N. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol. 1986 Nov 19;131(2-3):301–306. doi: 10.1016/0014-2999(86)90588-1. [DOI] [PubMed] [Google Scholar]
  7. Braun A., Fabbrini G., Mouradian M. M., Serrati C., Barone P., Chase T. N. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm. 1987;68(1-2):41–50. doi: 10.1007/BF01244638. [DOI] [PubMed] [Google Scholar]
  8. Cooper J. The Leyton obsessional inventory. Psychol Med. 1970 Nov;1(1):48–64. doi: 10.1017/s0033291700040010. [DOI] [PubMed] [Google Scholar]
  9. Creese I., Sibley D. R., Hamblin M. W., Leff S. E. The classification of dopamine receptors: relationship to radioligand binding. Annu Rev Neurosci. 1983;6:43–71. doi: 10.1146/annurev.ne.06.030183.000355. [DOI] [PubMed] [Google Scholar]
  10. Gershanik O., Heikkila R. E., Duvoisin R. C. Behavioral correlations of dopamine receptor activation. Neurology. 1983 Nov;33(11):1489–1492. doi: 10.1212/wnl.33.11.1489. [DOI] [PubMed] [Google Scholar]
  11. Jones-Gotman M., Milner B. Design fluency: the invention of nonsense drawings after focal cortical lesions. Neuropsychologia. 1977;15(4-5):653–674. doi: 10.1016/0028-3932(77)90070-7. [DOI] [PubMed] [Google Scholar]
  12. Kapur N., Butters N. Visuoperceptive deficits in long-term alcoholics and alcoholics with Korsakoff's psychosis. J Stud Alcohol. 1977 Nov;38(11):2025–2035. doi: 10.15288/jsa.1977.38.2025. [DOI] [PubMed] [Google Scholar]
  13. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 1979 Jan 11;277(5692):93–96. doi: 10.1038/277093a0. [DOI] [PubMed] [Google Scholar]
  14. Kistrup K., Gerlach J. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans. Pharmacol Toxicol. 1987 Sep;61(3):157–161. doi: 10.1111/j.1600-0773.1987.tb01795.x. [DOI] [PubMed] [Google Scholar]
  15. Lees A. J., Stern G. M. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020–1023. doi: 10.1136/jnnp.44.11.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Leff S. E., Hamblin M. W., Creese I. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states. Mol Pharmacol. 1985 Feb;27(2):171–183. [PubMed] [Google Scholar]
  17. Mailman R. B., Schulz D. W., Lewis M. H., Staples L., Rollema H., Dehaven D. L. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur J Pharmacol. 1984 May 18;101(1-2):159–160. doi: 10.1016/0014-2999(84)90044-x. [DOI] [PubMed] [Google Scholar]
  18. Martin J. B., Gusella J. F. Huntington's disease. Pathogenesis and management. N Engl J Med. 1986 Nov 13;315(20):1267–1276. doi: 10.1056/NEJM198611133152006. [DOI] [PubMed] [Google Scholar]
  19. Molloy A. G., Waddington J. L. Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology (Berl) 1984;82(4):409–410. doi: 10.1007/BF00427697. [DOI] [PubMed] [Google Scholar]
  20. Setler P. E., Sarau H. M., Zirkle C. L., Saunders H. L. The central effects of a novel dopamine agonist. Eur J Pharmacol. 1978 Aug 15;50(4):419–430. doi: 10.1016/0014-2999(78)90148-6. [DOI] [PubMed] [Google Scholar]
  21. Titus R. D., Kornfeld E. C., Jones N. D., Clemens J. A., Smalstig E. B., Fuller R. W., Hahn R. A., Hynes M. D., Mason N. R., Wong D. T. Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline. J Med Chem. 1983 Aug;26(8):1112–1116. doi: 10.1021/jm00362a005. [DOI] [PubMed] [Google Scholar]
  22. Walters J. R., Bergstrom D. A., Carlson J. H., Chase T. N., Braun A. R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987 May 8;236(4802):719–722. doi: 10.1126/science.2953072. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES